With the Spread of Wegovy and Mounjaro, Appetite Becomes Something to Manage
Customer Lifetime Value (LTV) Matters More Than Sales Volume

There was a time when eating three meals a day was taken for granted. People considered eating more and eating better as a sign of prosperity in life. Food companies competed to offer tastier, more abundant, and more convenient food options.


However, the food industry is now at a turning point. Consumers no longer desire to eat more. Zero-calorie beverages have become part of daily life, and blood sugar management and slow aging have become new standards for consumption. Even for a single meal, people now focus more on nutrition than quantity, and health takes precedence over simply feeling full. Recently, with the spread of GLP-1 class obesity treatments such as Wegovy and Mounjaro, even appetite itself has become something to be managed.


[Inside Chodong] The Era of Eating Less: Wegovy and the Food Industry View original image

In the United States, these changes are already visible in the numbers. According to global consulting firm KPMG, households taking GLP-1 medications consumed an average of 21% fewer calories than before, and grocery spending decreased by up to 31%. Obesity treatments have emerged as a variable that reduces not only individual weight but also overall food consumption. Global market research firm Euromonitor has diagnosed that humanity has entered the era of 'Peak Calorie,' where calorie consumption has passed its peak and is now declining. This year, second-quarter sales at U.S. food company Campbell's fell by 4.5% compared to the same period last year, and operating profit in the snack division plummeted by 39%.


The domestic market is no exception. Prescriptions for obesity treatments are increasing rapidly. According to data obtained by Assemblywoman Seo Mihwa of the Democratic Party of Korea from the Health Insurance Review and Assessment Service, there were 228,199 prescriptions for Mounjaro in March of this year, an increase of more than 11 times compared to August last year, the first month after its launch. The cumulative number of prescriptions for both drugs, including Wegovy, has surpassed 2 million. Usage of obesity treatments among teenagers is also on the rise. Data from the Health Insurance Review and Assessment Service show that the number of prescription checks for Mounjaro increased from 380 in October last year to 1,888 in March this year, a nearly fivefold increase. Prescriptions for Wegovy also rose from 914 to 2,213 during the same period, a 2.4-fold increase.


What is making the food industry even more anxious is the declining population. Last year, the population of South Korea naturally decreased by more than 120,000 people. Since 2020, the population has dropped by 456,000 over five years. The National Assembly Budget Office projects that the current population of 51.68 million will decrease to around 36.22 million by 2072.


There are fewer people to eat, and even those who remain are eating less. The food industry is facing an era of 'double decline.' What should food companies do to prepare? Amazon founder Jeff Bezos once said, "Strategy should be based on things that do not change," and added, "People ask me what will change in five or ten years, but rarely ask what will not change." In the food industry, one thing that will not change is that people will continue to seek healthier and better lives.



The transformation in the food industry is not just a passing trend. Now, the competition among food companies depends not on how much they sell, but on how long they remain the consumer's choice. The focus in the food industry is shifting from sales volume to customer lifetime value (LTV). Of course, pioneering overseas markets is also necessary. However, as it becomes more difficult to expand consumption in the domestic market, efforts to broaden business areas into health management and nutrition should be pursued in parallel.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing